Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Registration Number
- NCT00022620
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer.
- Detailed Description
OBJECTIVES:
* Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma.
* Determine the objective response and duration of response in patients treated with this regimen.
* Determine the acute side effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 12 weeks.
PROJECTED ACCRUAL: Approximately 16-29 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Allgemeines Krankenhaus der Stadt Wien
🇦🇹Vienna, Austria
Ospedale Mauriziano Umberto I
🇮🇹Torino, Italy
Queen Elizabeth Hospital
🇬🇧Gateshead, England, United Kingdom
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
Ospedale Civile
🇮🇹Voghera (PV), Italy
U.Z. Gasthuisberg
🇧🇪Leuven, Belgium
Hospitais da Universidade de Coimbra (HUC)
🇵🇹Coimbra, Portugal
Hospital Universitasrio San Carlos
🇪🇸Madrid, Spain